Results 141 to 150 of about 5,114,489 (264)

Risks and benefits in using zoledronic acid in patients with bone metastases [PDF]

, 2012
Dalia Zayed, Niveen Abo-Touk
openalex   +1 more source

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial [PDF]

, 2010
Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Kim Cocks, Sue Bell, Alex J. Szubert, Nuria Navarro-Coy, Mark T. Drayson, Roger G. Owen, Sylvia Feyler, A. John Ashcroft, Fiona Ross, Jenny Byrne, Huw Roddie, Claudius Rudin, Gordon Cook, Graham Jackson, J. Anthony Child   +17 more
openalex   +1 more source

Zoledronic Acid-Loaded β-TCP Inhibits Tumor Proliferation and Osteoclast Activation: Development of a Functional Bone Substitute for an Efficient Osteosarcoma Treatment [PDF]

, 2021
Yuka Kameda, Mamoru Aizawa, Taira Sato, Michiyo Honda   +3 more
openalex   +1 more source

Zoledronic acid in the management of metastatic bone disease

Therapeutics and Clinical Risk Management, 2008
Thomas J Polascik, Vladimir MouravievDuke Prostate Center and Division of Urologic Surgery, Duke University Medical Center, Durham, NC, USAAbstract: Many patients with advanced cancer experience decreased bone strength due to metastatic foci, underlying ...
Thomas J Polascik, Vladimir Mouraviev
doaj  

Use of Zoledronic Acid in a Neonate with Subcutaneous Fat Necrosis Complicated with Severe, Refractory Hypercalcemia [PDF]

, 2019
Maria Angela Militello, Maria Paola Re, Giuliana Vitaliti, Francesca Finazzo, Paolo Manzoni, Salvino Marcello Vitaliti   +5 more
openalex   +1 more source

Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status [PDF]

, 2015
Junko Kato, Manabu Futamura, M Kanematsu, Siqin Gaowa, Ryutaro Mori, Toshiyuki Tanahashi, Nobuhisa Matsuhashi, Kazuhiro Yoshida   +7 more
openalex   +1 more source

Supplementary Figure 4 from Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment <i>In Vivo</i>

, 2023
Penelope D. Ottewell, Ning Wang, Hannah K. Brown, Kimberly J. Reeves, C. Anne Fowles, Peter I. Croucher, Colby L. Eaton, Ingunn Holen   +7 more
openalex   +1 more source

Hepatotoxicity induced by zoledronic acid in an aged woman with primary osteoporosis [PDF]

, 2013
Zoledronic acid, a bisphosphonate, has been approved for treatment and prevention of osteoporosis. This case describes a 73-year-old woman with primary osteoporosis who developed transient hepatotoxicity after zoledronic acid (ZOL) treatment.
Fang, Fusheng, Jin, Mengmeng, Li, Chunlin, Li, Jian, Liu, Minyan, Lu, Yanhui, Ma, Lichao, Pei, Yu, Shao, Yinghong, Yan, Shuangtong   +9 more
core  

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women

Clinical Interventions in Aging, 2008
Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, GreeceAbstract: Zoledronic acid is a nitrogen-containing, third-generation ...
Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias   +4 more
doaj  

Bone Loss after Allogeneic Haematopoietic Stem Cell Transplantation: A Pilot Study on the Use of Zoledronic Acid [PDF]

, 2012
Andreas Hausmann, Wolfgang Hill, Hans‐Joachim Stemmler, Georg Ledderose, Andrea Baur‐Melnyk, Susanne Fritsch, J. Ullmann, Hans‐Jochem Kolb, Sandra Geiger, Johanna Tischer   +9 more
openalex   +1 more source